[1] ZHOU XL,FU JF. Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children[J].Chin J Pract Pediatr,2018,33(7):487-492.(in Chinese)周雪莲,傅君芬.儿童非酒精性脂肪肝病诊断与治疗专家共识[J].中国实用儿科杂志,2018,33(7):487-492.
|
[2] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1769.
|
[3] SOCHA P,JANCZYK W,DHAWAN A,et al. Wilson’s disease in children:A position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology,Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr,2018,66(2):334-344.
|
[4] GILBERT MA,BAUER RC,RAJAGOPALAN R,et al. Alagille syndrome mutation update:Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification[J]. Hum Mutat,2019,40(12):2197-2220.
|
[5] Neurology Branch of Chinese Medical Association; Study Group of Neuromuscular Diseases,Neurology Branch of Chinese Medical Association; Study Group of Electromyography and Clinical Neurophysiology,Neurology Branch of Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of pseudohypertrophic muscular dystrophy[J]. Chin J Neurol,2016,49(1):17-20.(in Chinese)中华医学会神经病学分会,中华医学会神经病学分会神经肌肉病学组,中华医学会神经病学分会肌电图与临床神经生理学组.中国假肥大型肌营养不良症诊治指南[J].中华神经科杂志,2016,49(1):17-20.
|
[6] DAGLI A,SENTNER CP,WEINSTEIN DA. Glycogen storage disease typeⅢ[M]. In:GeneReviews[Internet]. Seattle(WA):University of Washington,Seattle; 1993-2020.
|
[7] SCIVERES M,NASTASIO S,MAGGIORE G. Novel diagnostic and therapeutic strategies in juvenile autoimmune hepatitis[J]. Front Pediatr,2019,7:382.
|
[8] Study Group of Thrombosis and Hemostasis,Chinese Society of Hematology,Chinese Medical Association; Study Group of Children,Hemophilia Treatment Center Collaborative Network of China; Study Group of Hematology,Chinese Pediatric Society,Chinese Medical Association. Chinese expert guidelines for hemophilia in children(2017)[J]. Chin J Pract Pediatr,2017,32(1):1-5.(in Chinese)中华医学会血液学分会血栓与止血学组,中国血友病协作组儿童组,中华医学会儿科学分会血液学组.中国儿童血友病专家指导意见(2017年)[J].中国实用儿科杂志,2017,32(1):1-5.
|
[9] GREEN RM,FLAMM S. AGA technical review on the evaluation of liver chemistry tests[J]. Gastroenterology,2002,123(4):1367-1384.
|
[10] WANG G,FENG D. Dynamic relationship between infantile hepatitis syndrome and cytomegalovirus infection[J]. Exp Ther Med,2017,13(6):3443-3447.
|
[11] SOHN MJ,CHO JM,MOON JS,et al. EBV VCA IgM and cytomegalovirus IgM dual positivity is a false positive finding related to age and hepatic involvement of primary Epstein-Barr virus infection in children[J]. Medicine(Baltimore),2018,97(38):e12380.
|
[12] KOFTERIDIS DP,KOULENTAKI M,VALACHIS A,et al. Epstein Barr virus hepatitis[J]. Eur J Intern Med,2011,22(1):73-76.
|
[13] HEROLD J,GRIMALDO F. Epstein-Barr virus-induced jaundice[J]. Clin Pract Cases Emerg Med,2020,4(1):69-71.
|
[14] PODDIGHE D. Extra-pulmonary diseases related to Mycoplasma pneumoniae in children:Recent insights into the pathogenesis[J]. Curr Opin Rheumatol,2018,30(4):380-387.
|
[15] KIM KW,SUNG JJ,TCHAH H,et al. Hepatitis associated with Mycoplasma pneumoniae infection in Korean children:A prospective study[J]. Korean J Pediatr,2015,58(6):211-217.
|
[16] CLEMENTE MG,MANDATO C,POETA M,et al. Pediatric non-alcoholic fatty liver disease:Recent solutions,unresolved issues,and future research directions[J]. World J Gastroenterol,2016,22(36):8078-8093.
|
[17] WANG FS,FAN JG,ZHANG Z,et al. The global burden of liver disease:The major impact of China[J]. Hepatology,2014,60(6):2099-2108.
|
[18] CUZMAR V,ALBERTI G,UAUY R,et al. Early obesity:Risk factor for fatty liver disease[J]. J Pediatr Gastroenterol Nutr,2020,70(1):93-98.
|
[19] ZHANG HF,DONG Y,WANG LM,et al. A retrospective study on pathological and clinical characteristics of 3 932 children with liver diseases[J]. Chin J Pediatr,2014,52(8):570-574.(in Chinese)张鸿飞,董漪,王丽旻,等.儿童肝穿刺组织病理与临床诊断3932例回顾性研究[J].中华儿科杂志,2014,52(8):570-574.
|
[20] CHUGHLAY MF,KRAMER N,SPEARMAN CW,et al. Nacetylcysteine for non-paracetamol drug-induced liver injury:A systematic review[J]. Br J Clin Pharmacol,2016,81(6):1021-1029.
|
[21] YANG LX,LIU CY,ZHANG LL,et al. Clinical characteristics of patients with drug-induced liver injury[J]. Chin Med J(Engl),2017,130(2):160-164.
|
[22] ZHANG YF,GUO YM,NIU M,et al. Drug-induced liver injury in children:An analysis of medication and clinical features[J]. J Clin Hepatol,2019,35(3):579-584.(in Chinese)张艳芳,郭玉明,牛明,等.儿童药物性肝损伤的用药分析及临床特征[J].临床肝胆病杂志,2019,35(3):579-584.
|
[23] ZHU XX,ZHU Y,WAN CM. Clinical features of drug-induced liver injury in children[J]. Chin J Contemp Pediatr,2012,14(2):131-133.(in Chinese)朱欣欣,朱渝,万朝敏.儿童药物性肝损害的临床研究[J].中国当代儿科杂志,2012,14(2):131-133.
|
[24] GAN Y,DONG Y,ZHANG HF,et al. Clinical characteristics and outcomes of drug-induced liver injury in children:A study of 184 cases[J]. J Clin Hepatol,2015,31(8):1244-1247.(in Chinese)甘雨,董漪,张鸿飞,等.184例儿童药物性肝损伤的临床特征及转归状况评价[J].临床肝胆病杂志,2015,31(8):1244-1247.
|